Showing 1641-1650 of 3165 results for "".
- Soliton Takes On Cellulitehttps://practicaldermatology.com/news/soliton-takes-on-cellulite-2/2460049/Soliton, Inc.’s Rapid Acoustic Pulse ("RAP") device may selectively disrupt of the fibrotic septa that contribute to the appearance of cellulite, according to preclinical studies. The device is cleated for use in tattoo removal, howe
- Study: Teen Acne Linked to Better Gradeshttps://practicaldermatology.com/news/study-teen-acne-linked-to-better-grades/2460038/Individuals who had acne during their teen years earned higher grades in high school and were more likely to complete their bachelor’s degrees, according to a new study in the Journal of Human Capital.
- Crown Laboratories Unveils New Corporate Brandinghttps://practicaldermatology.com/news/crown-laboratories-unveils-new-corporate-branding/2460037/Crown Laboratories is launching its new corporate branding. Their new tagline 'Skin Science for Life' highlights the company’s focus on aesthetic medicine, generic and branded dermatological prescription drugs, OTC and prestig
- Sunscreen Chemicals Found in the Bloodstream: Experts React to the New Findingshttps://practicaldermatology.com/news/sunscreen-chemicals-found-in-bloodstream-experts-react-to-the-new-findings/2460023/Several active ingredients found in different sunscreens enter the bloodstream at levels that far exceed the FDA's recommended threshold without a government safety inspection, a new study in Journal of the American M
- Nextech Partners with RxPhoto for Integrated Image Managementhttps://practicaldermatology.com/news/nextech-partners-with-rxphoto-for-integrated-image-management/2459958/Nextech Systems has launched a new partnership with RxPhoto, a collaborative medical imagery solution. This partnership integrates RxPhoto’s patient photograph
- More Positive Results Seen with Endo's Injectable Cellulite Treatmenthttps://practicaldermatology.com/news/more-positive-results-for-endos-injectable-cellulite-treatment/2459965/Endo International plc’s injectable cellulite treatment collagenase clostridium histolyticum ("CCH") showed a clinically meaningful and statistically significant improvement compared to placebo for all primary and secondary endpoints in a Phase 2
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s